Datasea Lists NeuroVibe as FDA Class II Biofeedback Device
Beijing, China, August,11, 2026 Datasea Intelligent Technology Ltd. has announced that its variable interest entity, Shuhai Jingwei (Shenzhen) Information...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Beijing, China, August,11, 2026 Datasea Intelligent Technology Ltd. has announced that its variable interest entity, Shuhai Jingwei (Shenzhen) Information...
TORONTO, Canada, July 15, 2026 Cumulus Neuroscience has presented new clinical findings at the Alzheimer’s Association International Conference (AAIC)...
LONDON, UK, July 6, 2026 Cumulus Neuroscience announced a strategic collaboration with Muse by Interaxon to integrate validated at-home...
